SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 4, 2002
BIOTRANSPLANT INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE 000-28324 04-3119555
------------------------------- ------------------------ -------------------
(State or other jurisdiction of (Commission File Number) (IRS Employer
incorporation) Identification No.)
Building 75, Third Avenue
Charlestown Navy Yard
Charlestown, MA 02129
--------------------------------- -----------------------------
(Address of principal executive (Zip Code)
offices)
Registrant's telephone number, including area code: (617) 241-5200
N/A
---------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events.
On December 4, 2002, BioTransplant Incorporated issued a press release
announcing that it has agreed with Gambro BCT to terminate the companies'
distribution agreement for the EligixTM HDM Cell Separation Systems. See the
press release attached hereto as Exhibit 99.1.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) Exhibits.
See Exhibit Index attached hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: December 4, 2002 BIOTRANSPLANT INCORPORATED
By: /s/ DONALD B. HAWTHORNE
--------------------------
Donald B. Hawthorne
President and Chief Executive Officer
EXHIBIT INDEX
EXHIBIT NO. EXHIBIT
Exhibit 99.1 Press Release dated December 4, 2002